Latest News and Press Releases
Want to stay updated on the latest news?
-
NurExone Biologic Announces U.S. Uplisting Intention and Closes C$2.3 Million Private Placement
-
TORONTO and HAIFA, Israel, Feb. 19, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”) is proud to announce its inclusion in the 2025...
-
NurExone Biologic Inc. announces formation of a U.S.-based subsidiary, Exo-Top Inc. for fully characterized GMP Exosome production.
-
NurExone Secures C$1.2 Million through Warrant Exercises and Completion of Private Placement and Appoints New R&D Director
-
DOVER, DE, Dec. 13, 2024 (GLOBE NEWSWIRE) -- Pacific Green Technologies, Inc. ("Pacific Green"), (OTCQB: PGTK) announces that it has amended some material accounting policies following extensive...
-
NurExone Reports Third Quarter 2024 Financial Results and Provides Corporate Update
-
~ Announced RMAT designation for AMT-130 in Huntington’s disease and positive interim Phase I/II data demonstrating the slowing of disease progression and reductions in a key biomarker of...
-
TORONTO and HAIFA, Israel, July 05, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX), (OTCQB: NRXBF), (Germany: J90) (the “Company” or “NurExone”), a pioneering biopharmaceutical company,...
-
NurExone Reports First Quarter 2024 Financial Results and Provides Corporate Update, moving forward with FDA guidelines for the Human Trials
-
NurExone Reports Fourth Quarter and Year Ended December 31, 2023 Financial Results and Provides Company Update